Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 8/20 | 0.46 |
| ▸ | F2 | P00734 | 5/20 | 0.46 |
| ▸ | PLG | P00747 | 3/20 | 0.46 |
| ▸ | PLAU | P00749 | 3/20 | 0.46 |
| ▸ | PLAT | P00750 | 3/20 | 0.46 |
| ▸ | KLK8 | O60259 | 2/20 | 0.46 |
| ▸ | F10 | P00742 | 2/20 | 0.46 |
| ▸ | KLK4 | Q9Y5K2 | 2/20 | 0.46 |
| ▸ | TMPRSS6 | Q8IU80 | 3/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.45 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.45 |
| ▸ | KLK1 | P06870 | 1/20 | 0.43 |
| ▸ | KLK2 | P20151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24359705 | 0.85 | KDM4E (0.48) | PLAUKLK8KLK4KLK2 | |
| SCHEMBL3394756 | 0.78 | PLAU (0.63) | PRSS1F2PLGPLAUPLAT | |
| SCHEMBL24359520 | 0.77 | KDM4E (0.41) | PLAUKLK8KLK4KLK2 | |
| SCHEMBL8498158 | 0.76 | PRSS1 (0.58) | PRSS1F2TMPRSS6PRSS2PRSS3 | |
| SCHEMBL24359718 | 0.70 | KDM4E (0.36) | PLAUKLK8KLK4KLK2 | |
| SCHEMBL7329993 | 0.69 | MRGPRX1 (0.74) | MRGPRX1PRSS1F2F10TMPRSS6 | |
| SCHEMBL1363819 | 0.69 | F2 (0.56) | PRSS1F2PLGPLAUPLAT | |
| SCHEMBL2242403 | 0.69 | PLAU (0.67) | F2PLGPLAUPLATKLK8 | |
| Hydrochloric Acid SCHEMBL7387182 | 0.68 | F2 (0.55) | PRSS1F2PLGPLAUPLAT | |
| Hydrochloric Acid SCHEMBL7422244 | 0.68 | F2 (0.55) | PRSS1F2PLGPLAUPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060111553-A1 | Novel thrombin inhibitors, the preparation and use thereof | ABBOTT GMBH & CO. KG (DE) | 2006-05-25 | — | — | US | disclosed |
| US-6900319-B2 | Thrombin inhibitors | ABBOTT GMBH & CO. KG (DE) | 2005-05-31 | — | — | US | disclosed |
| US-6740647-B1 | AMIDINES AND HYDROXYAMIDINE DERIVATIVES | ABBOTT GMBH & CO., KG (DE) | 2004-05-25 | — | — | US | disclosed |
| US-20030004308-A1 | Novel thrombin inhibitors, the preparation and use thereof | BOHM HANS-JOACHIM (DE) | 2003-01-02 | — | — | US | disclosed |
| US-20020169318-A1 | Novel thrombin inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2002-11-14 | — | — | US | disclosed |
| US-6455671-B1 | COMPOUND FOR USE IN THE TREATMENT OF THROMBOSIS | ABBOTT LABORATORIES | 2002-09-24 | — | — | US | disclosed |
| US-6444817-B1 | ANTICOAGULANTS | ABBOTT LABORATORIES | 2002-09-03 | — | — | US | disclosed |
| US-6440937-B1 | COMPETITIVE INHIBITORS OF TRYPSIN-LIKE SERIN PROTEASES, ESPECIALLY THROMBIN AND KININOGENASES SUCH AS KALLIKREIN; THROMBIN INHIBITORS, ANTICOAGULANTS, AND ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES | 2002-08-27 | — | — | US | disclosed |
| US-6114358-A | Thrombin inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 2000-09-05 | — | — | US | disclosed |
| US-6030972-A | 2- OR 5-AMINOMETHYL,2- OR 5-CYANOPYRIMIDINES AS INTERMEDIATES OF ANTICOAGULANTS IN EXTRACORPOREAL CIRCULATION (HEART-LUNG MACHINE, HEMODIALYSIS) | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
| US-5952307-A | Basic α-aminoalkylphosphonate derivatives | GEORGIA TECH RESEARCH CORP. (US) | 1999-09-14 | — | — | US | disclosed |
| US-5686419-A | SERINE PROTEASE INHIBITOR ANTICOAGULANTS | GEORGIA TECH RESEARCH CORP. (US) | 1997-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111553-A1 | Novel thrombin inhibitors, the preparation and use thereof | TFPI, F2, TFPI2 | MRGPRX1 496/4885PRSS1 34/4885F2 2/4885 |
| US-20030004308-A1 | Novel thrombin inhibitors, the preparation and use thereof | TFPI, SERPINC1, F2 | MRGPRX1 395/4885PRSS1 29/4885F2 3/4885 |
| US-20020169318-A1 | Novel thrombin inhibitors | TFPI, SERPINC1, F11 | MRGPRX1 305/4885PRSS1 53/4885F2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.